[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3713919T3 - Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid - Google Patents

Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid Download PDF

Info

Publication number
DK3713919T3
DK3713919T3 DK18821779.8T DK18821779T DK3713919T3 DK 3713919 T3 DK3713919 T3 DK 3713919T3 DK 18821779 T DK18821779 T DK 18821779T DK 3713919 T3 DK3713919 T3 DK 3713919T3
Authority
DK
Denmark
Prior art keywords
cyclopropylmethyl
sulfonamide
quinoline
piperazine
carbonyl
Prior art date
Application number
DK18821779.8T
Other languages
English (en)
Inventor
Jacob P Sizemore
Mahmoud Mirmehrabi
Yeqing Su
Liting Guo
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3713919T3 publication Critical patent/DK3713919T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18821779.8T 2017-11-22 2018-11-21 Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid DK3713919T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US201862691709P 2018-06-29 2018-06-29
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Publications (1)

Publication Number Publication Date
DK3713919T3 true DK3713919T3 (da) 2023-09-25

Family

ID=64734113

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18821779.8T DK3713919T3 (da) 2017-11-22 2018-11-21 Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid

Country Status (26)

Country Link
US (2) US11254652B2 (da)
EP (2) EP3713919B1 (da)
JP (2) JP7275130B2 (da)
KR (2) KR102682430B1 (da)
CN (2) CN117551030A (da)
AU (2) AU2018373122B2 (da)
BR (1) BR112020010185A2 (da)
CA (1) CA3081945A1 (da)
DK (1) DK3713919T3 (da)
ES (1) ES2959764T3 (da)
FI (1) FI3713919T3 (da)
HR (1) HRP20230931T1 (da)
HU (1) HUE063264T2 (da)
IL (2) IL274488B2 (da)
LT (1) LT3713919T (da)
MD (1) MD3713919T2 (da)
MX (2) MX2020005348A (da)
PH (1) PH12020550644A1 (da)
PL (1) PL3713919T3 (da)
PT (1) PT3713919T (da)
RS (1) RS64592B1 (da)
SG (1) SG11202004587XA (da)
SI (1) SI3713919T1 (da)
TW (2) TW202334115A (da)
UA (1) UA127502C2 (da)
WO (1) WO2019104134A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3708169A1 (en) * 2009-06-29 2020-09-16 Agios Pharmaceuticals, Inc. 2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide derivatives having an anticancer activity
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
CN113166060B (zh) 2018-09-19 2024-01-09 诺沃挪第克健康护理股份公司 用丙酮酸激酶激活化合物治疗镰状细胞病
MX2021014228A (es) * 2019-05-22 2022-02-21 Agios Pharmaceuticals Inc Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida.
US11878049B1 (en) * 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
US20230098234A1 (en) 2020-01-28 2023-03-30 Teva Pharmaceuticals International Gmbh Solid state forms of mitapivat and process for preparation thereof
JP2023542701A (ja) * 2020-09-25 2023-10-11 アジオス ファーマシューティカルズ， インコーポレイテッド 薬学的製剤
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
TW202308630A (zh) 2021-04-30 2023-03-01 美商阿吉歐斯製藥公司 用於滴定米塔皮瓦的方法
WO2023154036A1 (en) 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
EP4433057A1 (en) 2021-11-16 2024-09-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
WO2024084501A1 (en) 2022-10-17 2024-04-25 Mylan Laboratories Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (da) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
EP3708169A1 (en) * 2009-06-29 2020-09-16 Agios Pharmaceuticals, Inc. 2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide derivatives having an anticancer activity
ME03074B (me) 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) * 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
CN111728971A (zh) 2012-09-18 2020-10-02 奥斯拜客斯制药有限公司 D6-四苯喹嗪固体口服剂型、化合物、及其药物组合物、制备及治疗方法
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Also Published As

Publication number Publication date
EP3713919B1 (en) 2023-08-02
EP3713919A1 (en) 2020-09-30
RS64592B1 (sr) 2023-10-31
ES2959764T3 (es) 2024-02-28
CA3081945A1 (en) 2019-05-31
FI3713919T3 (fi) 2023-09-29
SI3713919T1 (sl) 2023-10-30
CN111372920B (zh) 2023-10-20
JP2023093762A (ja) 2023-07-04
WO2019104134A1 (en) 2019-05-31
KR102682430B1 (ko) 2024-07-08
IL274488B2 (en) 2024-01-01
IL274488A (en) 2020-06-30
CN111372920A (zh) 2020-07-03
AU2018373122A1 (en) 2020-05-21
CN117551030A (zh) 2024-02-13
TWI808108B (zh) 2023-07-11
MX2022009998A (es) 2022-09-19
HUE063264T2 (hu) 2024-01-28
JP2021504338A (ja) 2021-02-15
MD3713919T2 (ro) 2024-02-29
BR112020010185A2 (pt) 2021-01-12
US20200277279A1 (en) 2020-09-03
PT3713919T (pt) 2023-10-26
PH12020550644A1 (en) 2021-04-26
US20220220093A1 (en) 2022-07-14
UA127502C2 (uk) 2023-09-13
EP4285904A2 (en) 2023-12-06
IL274488B1 (en) 2023-09-01
KR20240108581A (ko) 2024-07-09
HRP20230931T1 (hr) 2023-11-24
TW201930289A (zh) 2019-08-01
PL3713919T3 (pl) 2023-12-27
SG11202004587XA (en) 2020-06-29
TW202334115A (zh) 2023-09-01
JP7275130B2 (ja) 2023-05-17
AU2024200724A1 (en) 2024-02-22
IL305343A (en) 2023-10-01
LT3713919T (lt) 2023-10-10
KR20200090787A (ko) 2020-07-29
EP4285904A3 (en) 2023-12-20
MX2020005348A (es) 2020-08-13
US11254652B2 (en) 2022-02-22
AU2018373122B2 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
DK3713919T3 (da) Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid
DK3866587T3 (da) Overvågning af husdyr
DK3883936T3 (da) Nye heterocykliske forbindelser
DK3515297T3 (da) Biosymmetrisk sammenligning af subepidermale fugtværdier
DK3371171T3 (da) Inhibitorer af RET
DK3596042T3 (da) Krystalformer af aminolipider
DK3565806T3 (da) Nye phenylderivater
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3833662T3 (da) Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
DK3891145T3 (da) Modulatorer af trex1
DK3600499T3 (da) Overvågning af en injektionsproces
DK3513617T3 (da) Håndtering af PDCP under genetablering af forbindelse
DK3697418T3 (da) Forbedrede formuleringer af bromocriptin
DK3529236T3 (da) Krystalformer af eravacyclin
DK3759745T3 (da) Dannelse af piezoelektriske anordninger
DK3613436T3 (da) Oral suspension af temozolomid
DK3678644T3 (da) Formuleringer af copanlisib
DK3580197T3 (da) Oprensning af pleuromutilin
DK3430004T3 (da) Faststofformer af nilotinibsalte
DK3743064T3 (da) Behandling af proteinuri
DK3749673T3 (da) Krystallinsk form af bictegravir-natrium
DK3853219T3 (da) Herbicidt virksomme substituerede phenylpyrimidinhydrazider